Opigolix
Chemical compound
Clinical data | |
---|---|
Other names | ASP-1707 |
Routes of administration | By mouth |
Drug class | GnRH modulator; GnRH antagonist; Antigonadotropin |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C25H19F3N4O5S |
Molar mass | 544.51 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
|
Opigolix (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name ASP-1707) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis.[1][2] It was also under investigation for the treatment of prostate cancer.[1] It reached phase II clinical trials for both endometriosis and rheumatoid arthritis prior to the discontinuation of its development in April 2018.[1]
See also
References
- ^ a b c "Opigolix - Astellas Pharma - AdisInsight".
- ^ Ezzati M, Carr BR (2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Women's Health. 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052.
External links
- Opigolix - AdisInsight
- v
- t
- e
GnRHTooltip Gonadotropin-releasing hormone and gonadotropins
(incl. analogues)
Agonists | |
---|---|
Antagonists |
|
Preparations |
---|
(indirect)
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- GnRH and gonadotropin receptor modulators
- Androgens and antiandrogens
- Estrogens and antiestrogens
- Progestogens and antiprogestogens
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e